Johnson & Johnson therapy nipocalimab granted U.S. FDA Fast Track designation in systemic lupus erythematosus (SLE)PRNewsWire • 03/03/26
4 Large-Cap Pharma Stocks to Watch as Industry Recovery Gains SteamZacks Investment Research • 03/02/26
Johnson & Johnson (JNJ) Advances While Market Declines: Some Information for InvestorsZacks Investment Research • 02/27/26
Early study results from Johnson & Johnson show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancerPRNewsWire • 02/26/26
Johnson & Johnson seeks FDA approval of IMAAVY® (nipocalimab-aahu) as the first-ever FDA-approved treatment for warm autoimmune hemolytic anemia (wAIHA)PRNewsWire • 02/24/26
Wall Street Bulls Look Optimistic About Johnson & Johnson (JNJ): Should You Buy?Zacks Investment Research • 02/24/26
Bayer Alleges J&J's Claims Regarding NUBEQA® are Deeply Flawed and Intentionally Aimed at Boosting Sales of J&J's ERLEADABusiness Wire • 02/23/26
Johnson & Johnson vs. AbbVie: A Growth Showdown Amid Patent CliffsZacks Investment Research • 02/23/26
Johnson & Johnson: This Dividend King Could Anchor a Millionaire Retirement PortfolioThe Motley Fool • 02/22/26
The Only Healthcare Stock I'd Buy and Never Sell Might Be Johnson & JohnsonThe Motley Fool • 02/22/26
TREMFYA® (guselkumab) long-term data show sustained clinical and endoscopic remission in ulcerative colitis through 3 yearsPRNewsWire • 02/21/26
Why Is Johnson & Johnson (JNJ) Up 13% Since Last Earnings Report?Zacks Investment Research • 02/20/26
Q4 Healthcare Dividends: Johnson & Johnson Kept Outshining Pfizer (Rating Upgrades)Seeking Alpha • 02/19/26
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus immunotherapy shows strong clinical benefit with 56 percent overall response rate in first-line recurrent or metastatic head and neck cancerPRNewsWire • 02/19/26